Medicine for treating advanced refractory solid tumors with TP53 mutation and application

Abstract

The invention belongs to the technical field of precision medicine, and discloses a medicine for treating advanced refractory solid tumors with TP53 mutation and application. The medicine for treatingthe advanced refractory solid tumors with TP53 mutation comprises apatinib and olaparib. AN anti-angiogenesis medicine is combined with a PARP inhibitor to treat the advanced solid tumors with TP53 mutation, and magical curative effects are achieved. The anti-angiogenesis medicine combined with the PARP inhibitor shows a certain anti-cancer curative effect in preclinical research. The anti-angiogenesis medicine can down-regulate homologous recombination repair related genes such as BRCA and RAD51, can make cells in a hypoxic state, and can enhance the treatment effect of the PARP inhibitor.

Description

technical field [0001] The invention belongs to the technical field of precision medicine, and in particular relates to a medicine and application for treating advanced refractory solid tumors with TP53 mutation. Background technique [0002] Currently, the closest prior art: In human tumors, TP53 mutation is the most common tumor suppressor gene mutation, with a mutation frequency ranging from 10% to 96%. Harmful mutations in TP53 lead to cell cycle arrest and impaired DNA damage repair function, leading to overexpression of target genes and genome instability, thereby promoting the occurrence and development of tumors. However, there is currently no effective way to treat tumors with TP53 mutations. Therefore, an effective therapeutic strategy that can target TP53-mutant tumors is urgently needed to improve the condition and prolong survival of such patients. Angiogenesis promotes the growth and spread of cancer cells and plays an important role in tumor formation and pr...

AI Technical Summary

Problems solved by technology

The reason is that all patients need to undergo genetic testing to detect TP53 mutations. The current genetic testing technology needs to be further standardized and the testing price is relatively high. In addition, the price of targeted drugs is also relatively high. As targeted drugs are gradually included in medical insurance reimbursement, this problem should be resolved

[0004] In summary, the existing problems in the prior art are: currently commonly used anti-angiogenic drugs include pazopanib, sorafenib, sunitinib, apatinib, axitinib, bevacizumab etc., lack of specific target

[0005] Difficulty in solving the above technical problems: To solve the problem of lack of specific targets for anti-angiogenic drugs, more cell biology experiments and animal experiments are needed. This may take a long time, and it may not be smooth after the exploration. Invention may have to find another way

Images